Cardiometabolic diseases

Cardiometabolic diseases are one of the greatest challenges we face. Our focus lies in countering the threat through innovative diagnostic, therapies and preventive solutions.

Challenge

Cardiovascular and metabolic (CVM) diseases are an ever-growing public health emergency. They impact at least half of the global population and significantly contribute to poor health and premature death. In addition, CVM diseases place huge direct and indirect costs on patients, their caregivers and society. 

Despite numerous treatment options, the trajectory for people with CVM disease has not changed significantly - these conditions remain underdiagnosed, undertreated and poorly prioritised on national health agendas so their impact on society continues to grow and remains the largest burden to public health. Scientific understanding of the biology of CVM diseases continues to highlight their complex interplay confirming it is not a single ailment, but rather a spectrum of conditions1, 2 and early intervention is crucial to prevent complications.

Focus

With Diagnostics and Pharma under the same roof, Roche is uniquely positioned to support people living with CVM diseases at every step of their way. From diagnosis, to treatment through to monitoring.

We are rapidly expanding our footprint in CVM by building on our legacy and knowledge in this field to address current and future challenges with a comprehensive pipeline of diagnostics to support early intervention and improve outcomes and transformative investigational medicines which are demonstrating early, emerging benefits for patients.

We are developing transformative standards of care to change the trajectory and therefore improve the outcomes for people living with CVM diseases as well as reduce their significant burden on society. Advanced technologies and our evolving understanding of disease present new opportunities to personalise treatment, reduce unnecessary costs, and protect people in their time of need.

References:

  1. American College for Cardiology. Cardiometabolic Initiatives. https://www.acc.org/tools-and-practice-support/quality-programs/cardiometabolic-health-alliance. Accessed March 9, 2021.

  2. A Presidential Advisory From the American Heart Association

See more stories

More focus areas

View all focus areas

Discover more

For Diagnostics customers

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeCovid-19Pharma solutionsRoche careersMedia libraryAnnual Report 2023Privacy policyLegal statementAccessibility statement